Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897588255> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2897588255 abstract "Objective: To evaluate plasma NfL levels in patients with RMS participating in RADIANCE Part A. Background: Ozanimod, a once-daily, oral immunomodulator that selectively targets sphingosine 1-phosphate receptor 1 (S1P R1 ) and 5 (S1P R5 ), has shown therapeutic benefit in clinical studies of RMS. Modulation of S1P R1 on lymphocytes may disrupt the inflammatory cascade of MS. NfL, which is released into cerebrospinal fluid and serum/plasma following axonal/neuronal injury, may serve as a putative biomarker for neurologic damage. Design/Methods: In RADIANCE Part A (NCT01628393), patients with RMS were randomized (1:1:1) to once-daily oral ozanimod 0.5 mg (n=87) or 1.0 mg (n=83) or placebo (n=88) for 24 weeks. The primary endpoint was mean cumulative number of gadolinium-enhancing lesions from weeks 12–24. Mean cumulative number of new/enlarging T2 lesions from weeks 12–24 was a secondary endpoint. Plasma NfL was measured at baseline and week 24 using Simoa technology. Results: At baseline, median plasma NfL was 12.33, 12.33, and 11.69 pg/mL for ozanimod 0.5 mg, ozanimod 1.0 mg, and placebo, respectively. Higher baseline NfL was associated with greater baseline gadolinium-enhancing lesion counts and T2 lesion volume. Median plasma NfL at week 24 was 9.39, 9.28, and 11.77 pg/mL, respectively. The decrease in NfL levels from baseline to week 24 differed significantly for ozanimod 0.5 mg (p=0.0048) and 1.0 mg (p=0.0087) vs. placebo. Relative to placebo, both ozanimod doses reduced the mean cumulative numbers of gadolinium-enhancing (both p Conclusions: Both ozanimod doses significantly reduced NfL levels between baseline and week 24 by 25% vs. placebo. These declines may correlate with the clinically significant reductions in new gadolinium-enhancing and new/enlarging T2 lesion development over weeks 12–24 seen with ozanimod. These data suggest that plasma NfL is a biomarker of brain lesion activity, but additional studies are needed. Study Supported by: Celgene Disclosure: Dr. Taylor Meadows has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Celgene. Dr. Taylor Meadows holds stock and/or stock options in Celgene, which sponsored research in which Dr. Taylor Meadows was involved as an investigator. Dr. Taylor Meadows has received research support from Celgene. Dr. Skolnick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Celgene. Dr. Frohna has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Celgene. Dr. Aranda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Celgene. Dr. Southworth has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with celgene, GSk, astrazeneca, ardea, university of Manchester, university of Lancaster, clarostat Ltd, alphamedstat ltd, stone biostatistics Ltd, allecra. Dr. Opiteck has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Celgene." @default.
- W2897588255 created "2018-10-26" @default.
- W2897588255 creator A5007313865 @default.
- W2897588255 creator A5038297657 @default.
- W2897588255 creator A5046934563 @default.
- W2897588255 creator A5049364434 @default.
- W2897588255 creator A5049856160 @default.
- W2897588255 creator A5080773253 @default.
- W2897588255 date "2018-04-10" @default.
- W2897588255 modified "2023-09-25" @default.
- W2897588255 title "Ozanimod (RPC1063) Reduces Plasma Levels of Neurofilament Light Chain (NfL) in Patients With Relapsing Multiple Sclerosis (RMS): Results From RADIANCE Part A, a Randomized, Placebo-Controlled, Phase 2 Study (P3.395)" @default.
- W2897588255 hasPublicationYear "2018" @default.
- W2897588255 type Work @default.
- W2897588255 sameAs 2897588255 @default.
- W2897588255 citedByCount "0" @default.
- W2897588255 crossrefType "journal-article" @default.
- W2897588255 hasAuthorship W2897588255A5007313865 @default.
- W2897588255 hasAuthorship W2897588255A5038297657 @default.
- W2897588255 hasAuthorship W2897588255A5046934563 @default.
- W2897588255 hasAuthorship W2897588255A5049364434 @default.
- W2897588255 hasAuthorship W2897588255A5049856160 @default.
- W2897588255 hasAuthorship W2897588255A5080773253 @default.
- W2897588255 hasConcept C126322002 @default.
- W2897588255 hasConcept C142724271 @default.
- W2897588255 hasConcept C168563851 @default.
- W2897588255 hasConcept C185592680 @default.
- W2897588255 hasConcept C203092338 @default.
- W2897588255 hasConcept C204787440 @default.
- W2897588255 hasConcept C27081682 @default.
- W2897588255 hasConcept C2781197716 @default.
- W2897588255 hasConcept C55493867 @default.
- W2897588255 hasConcept C71924100 @default.
- W2897588255 hasConcept C90924648 @default.
- W2897588255 hasConceptScore W2897588255C126322002 @default.
- W2897588255 hasConceptScore W2897588255C142724271 @default.
- W2897588255 hasConceptScore W2897588255C168563851 @default.
- W2897588255 hasConceptScore W2897588255C185592680 @default.
- W2897588255 hasConceptScore W2897588255C203092338 @default.
- W2897588255 hasConceptScore W2897588255C204787440 @default.
- W2897588255 hasConceptScore W2897588255C27081682 @default.
- W2897588255 hasConceptScore W2897588255C2781197716 @default.
- W2897588255 hasConceptScore W2897588255C55493867 @default.
- W2897588255 hasConceptScore W2897588255C71924100 @default.
- W2897588255 hasConceptScore W2897588255C90924648 @default.
- W2897588255 hasLocation W28975882551 @default.
- W2897588255 hasOpenAccess W2897588255 @default.
- W2897588255 hasPrimaryLocation W28975882551 @default.
- W2897588255 hasRelatedWork W14941675 @default.
- W2897588255 hasRelatedWork W1549044103 @default.
- W2897588255 hasRelatedWork W1565997261 @default.
- W2897588255 hasRelatedWork W1729832269 @default.
- W2897588255 hasRelatedWork W2530854562 @default.
- W2897588255 hasRelatedWork W2554081667 @default.
- W2897588255 hasRelatedWork W2803952614 @default.
- W2897588255 hasRelatedWork W2805066472 @default.
- W2897588255 hasRelatedWork W2806687972 @default.
- W2897588255 hasRelatedWork W2808055426 @default.
- W2897588255 hasRelatedWork W2809418345 @default.
- W2897588255 hasRelatedWork W2885430857 @default.
- W2897588255 hasRelatedWork W2888596619 @default.
- W2897588255 hasRelatedWork W2898365980 @default.
- W2897588255 hasRelatedWork W2900129824 @default.
- W2897588255 hasRelatedWork W2910564004 @default.
- W2897588255 hasRelatedWork W2921858277 @default.
- W2897588255 hasRelatedWork W3015657679 @default.
- W2897588255 hasRelatedWork W3161670146 @default.
- W2897588255 hasRelatedWork W3166282819 @default.
- W2897588255 hasVolume "90" @default.
- W2897588255 isParatext "false" @default.
- W2897588255 isRetracted "false" @default.
- W2897588255 magId "2897588255" @default.
- W2897588255 workType "article" @default.